Holdings Channel
Home Articles Latest Filings All Funds Stocks Being Bought Stocks Being Sold Insider Buying
Play Video: The Importance of Insider Buying


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
BIOC — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree BIOC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

BIOC — Performance
Biocept insider buying image
The table below summarizes the most recent Biocept insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Biocept insider buys are important for investors to follow.
DateInsiderPriceAmount
3-16-2015
Insider Buy		 Ivor Royston
Director		 $8.76
CAGR » 		$49,642.92
5,667 shares
10-19-2016
Insider Buy		 Michael W. Nall
CEO & President		 $1.10
CAGR » 		$39,999.30
36,363 shares
10-19-2016
Insider Buy		 Margaret Faye Wilson
Director		 $1.10
CAGR » 		$14,999.60
13,636 shares
10-19-2016
Insider Buy		 Lyle J. Arnold
SR VP of R&D and CSO		 $1.10
CAGR » 		$49,500.00
45,000 shares
10-19-2016
Insider Buy		 Veena Singh
Sr VP & Sr Med Director		 $1.10
CAGR » 		$11,000.00
10,000 shares
10-19-2016
Insider Buy		 Bruce Gerhardt
Director		 $1.10
CAGR » 		$55,000.00
50,000 shares
10-19-2016
Insider Buy		 Bruce A. Huebner
Director		 $1.10
CAGR » 		$22,000.00
20,000 shares
10-19-2016
Insider Buy		 Timothy Kennedy
CFO, Sr V.P. Operations & Sec.		 $1.10
CAGR » 		$39,999.30
36,363 shares
10-19-2016
Insider Buy		 Marsha Alpert Chandler
Director		 $1.10
CAGR » 		$4,999.50
4,545 shares
10-19-2016
Insider Buy		 Claire Reiss
>10% Owner		 $1.10
CAGR » 		$249,999.20
227,272 shares
10-19-2016
Insider Buy		 David F. Hale
Director		 $1.10
CAGR » 		$99,999.90
90,909 shares
10-19-2016
Insider Buy		 Edward A. Neff
Director		 $1.10
CAGR » 		$249,999.20
227,272 shares
5-4-2016
Insider Buy		 Claire Reiss
>10% Owner		 $1.00
CAGR » 		$614,273.00
614,273 shares
5-4-2016
Insider Buy		 Bruce Gerhardt
Director		 $1.00
CAGR » 		$25,000.00
25,000 shares
5-4-2016
Insider Buy		 Edward A. Neff
Director		 $1.00
CAGR » 		$100,000.00
100,000 shares
5-4-2016
Insider Buy		 David F. Hale
Director		 $1.00
CAGR » 		$50,000.00
50,000 shares
6-1-2015
Insider Buy		 Veena Singh
Sr VP & Sr Med Director		 $3.08
CAGR » 		$15,410.00
5,000 shares
2-13-2015
Insider Buy		 Marsha Alpert Chandler
Director		 $1.25
CAGR » 		$2,500.00
2,000 shares
2-13-2015
Insider Buy		 Bruce Gerhardt
Director		 $1.25
CAGR » 		$25,000.00
20,000 shares
2-13-2015
Insider Buy		 David F. Hale
Chairman		 $1.25
CAGR » 		$50,000.00
40,000 shares
2-13-2015
Insider Buy		 Bruce A. Huebner
Director		 $1.25
CAGR » 		$15,000.00
12,000 shares
2-13-2015
Insider Buy		 Michael W. Nall
CEO & President		 $1.25
CAGR » 		$15,000.00
12,000 shares
2-13-2015
Insider Buy		 Edward A. Neff
Director		 $1.25
CAGR » 		$50,000.00
40,000 shares
2-13-2015
Insider Buy		 Ivor Royston
Director		 $1.25
CAGR » 		$15,000.00
12,000 shares
2-13-2015
Insider Buy		 Margaret Faye Wilson
Director		 $1.25
CAGR » 		$5,000.00
4,000 shares
12-16-2011
Insider Buy		 Marcella Locastro
Director		 $4.49
CAGR » 		$6,735.00
1,500 shares
12-15-2011
Insider Buy		 Marcella Locastro
Director		 $4.45
CAGR » 		$7,787.50
1,750 shares
12-7-2011
Insider Buy		 Wallace P. Parker Jr.
Director		 $4.25
CAGR » 		$4,250.00
1,000 shares
12-5-2011
Insider Buy		 Wallace P. Parker Jr.
Director		 $4.37
CAGR » 		$13,110.00
3,000 shares
11-22-2011
Insider Buy		 Wallace P. Parker Jr.
Director		 $4.40
CAGR » 		$4,400.00
1,000 shares

Also See: Institutional Holders of BIOC
Also See: SEC filings

BIOC Performance Since Insider Purchase
Below we present the annualized performance delivered by Biocept stock since 3-16-2015 (the date of the most recent insider purchase). The performance of the investment from the time Biocept insider buying occurred is the ultimate test of whether insiders were right about BIOC being a good buy.

Growth of $10,000.00
Without Dividends Reinvested
Start date: 03/17/2015
End date: 10/24/2023
Start price/share: $64,530.00
End price/share: $0.43
Dividends collected/share: $0.00
Total return: -100.00%
Average Annual Total Return: -74.95%
Starting investment: $10,000.00
Ending investment: $0.07
Years: 8.61

Biocept Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Biocept insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding BIOC

Biocept Insider Buying | www.HoldingsChannel.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in Holdings Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent. Contact Holdings Channel; Meet Our Editorial Staff.